

# Partner Search Form

## Horizon Europe

### Health

Date | July 7, 2025  
Deadline | N/A

#### CONTACT

Organisation	BioCanRx Canada's Immunotherapy Network	Department	Not applicable
Contact person	Dr. Megan Mahoney	Email	<a href="mailto:memahoney@biocanrx.com">memahoney@biocanrx.com</a>
City	Ottawa	Website	BioCanRx.com
Country	CANADA		

#### Organisation type

Research organisation type	<input checked="" type="checkbox"/> Research Organisation <input type="checkbox"/> University <input type="checkbox"/> Company <input checked="" type="checkbox"/> Other NOT FOR PROFIT GOVERNMENT-FUNDED ENTITY	Is your company a Small and Medium Sized Enterprise (SME*)?  Number of employees:	<input type="checkbox"/> YES <input checked="" type="checkbox"/> NO  Not applicable
----------------------------	---	---	---

Your enterprise is an SME if:

- it is engaged in **economic activity**
- it has **less than 250 employees**
- it has either an **annual turnover not exceeding €50M**, or an **balance sheet total not exceeding €43M**
- it is **autonomous**

For the definition of SMEs, look at: [http://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition\\_en](http://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en)

**Partner Search Form**  
**Horizon Europe**  
**Health**

**Short introduction of key areas of institute's research:**

**Alignment to Health Cluster:** BioCanRx is a national leader in Canada advancing the development, translation, and clinical integration of cancer ATMPs, and other biotechnology-derived therapies. Our network brings together leading Canadian experts across disciplines—spanning discovery science, translational development, clinical research, health economics, and biomanufacturing. We aim to leverage this collective expertise to contribute meaningfully to Horizon Europe's Health Cluster objectives, particularly in areas targeting cancer, advanced therapeutic development, and improved access to innovative care. BioCanRx is well-positioned to act as a Canadian "match-maker" and subject matter liaison, connecting international consortia with relevant expertise, platforms, and partnerships aligned with Horizon Europe calls.

**About BioCanRx:** BioCanRx is Canada's Immunotherapy Network, dedicated to transforming cancer into a curable disease. We operate as a pan-Canadian national translational research engine that is accelerating the development of academically developed cancer biotherapeutics from bench to bedside. We invest in collaborative, multidisciplinary projects and strategic initiatives that encompass proof-of-concept and preclinical validation research to process development and biomanufacturing, early-phase clinical trials, and health system integration. Through access to funding, translational expertise, GMP infrastructure, and specialized training programs, we accelerate Canadian innovations to reach patients faster. BioCanRx is supported by the Government of Canada, with additional contributions from provinces, industry, and philanthropic organizations.

**Highlights of our investments and strategic objectives:**

- Investments in cutting-edge cancer immunotherapies, including cancer vaccines, oncolytic viruses, adoptive cell therapies (e.g., CAR-T, TIL), *in-vivo* editing platforms, and biomanufacturing enhancements (e.g., to increase viral vector yield)
- Leading efforts to expand access to made-in-Canada CAR T cell therapies through Canadian Led Immunotherapies in Cancer (CLIC) national program
- Policy, regulatory and patient engagement to innovate on health system adoption pathways for rare cancer therapy
- Funding to support standardization of release tests for ATMPs in early-phase clinical trials
- Operational support to Canadian academic core facilities supporting: process development and GMP biomanufacturing of viral vectors and CAR T cell therapies, and other cell-based products, lab-grade monoclonal antibody development, and correlative and immune monitoring of clinical patient samples.

**Former participation in an FP European project?**

 **NO**

**Project title / Acronym:** Not applicable

**Activities performed:** Not applicable

<b>Expertise / Commitment offered</b>
---------------------------------------

<b>Description of your expertise:</b>
---------------------------------------

**Call topic(s):**

**For each of the call topics, we have outlined specific projects, initiatives and policy work that BioCanRx is supporting.**

**HORIZON-HLTH-2025-01-IND-01 - [Optimising the manufacturing of Advanced Therapy Medicinal Products \(ATMPs\)](#)**

- academic-industry led development of **small molecules that increase viral vector yield**
- establishment of a **Canadian Quality Control (QC) platform** for CAR T cells and other cancer ATMPs destined for early-phase clinical trials
- hospital-based manufacturing processes for TIL and CAR T cell products (EC1394/2007 sCTMP and GTMP categories are of interest and alignment to BioCanRx)
  - spear-heading the CLIC (Canadian Led Immunotherapies in Cancer) national program initiative to manufacture CAR T in decentralized and hospital-based settings
- **operational support** to Canadian academic **core facilities**: process development and GMP biomanufacturing of viral vectors, CAR T for early-phase clinical trials, and other cell-based products, lab-grade monoclonal antibody development, and correlative and immune monitoring of clinical patient samples.

**HORIZON-HLTH-2025-01-TOOL-02 - [Advancing cell secretome-based therapies](#)**

- BioCanRx is supporting an academic-industry led project for a virally programmed **exosome-based cancer vaccine**. This project has completed development work and is underway with enabling studies to support a **CMC package and Clinical Trial application** to Health Canada.

**HORIZON-HLTH-2025-01-TOOL-05 - [Boosting the translation of biotech research into innovative health therapies](#)**

- BioCanRx is a **translational research network** with funded early-phase cancer immunotherapy clinical trials and trial sites across Canada. We could **serve as a facilitator of expertise and infrastructure** for the conduct of these biotech clinical trials, and/or with Canadian SMEs.
- Facilitator of expertise in Canada with respect to Canadian commercialization strategy and health system adoption
- **Technologies of interest** include: therapeutic vaccines, combination therapies (i.e., with monoclonal antibodies, ATMPs (e.g., CAR T cell therapies), and RNA based therapies.

**HORIZON-MISS-2025-02-CANCER-04 - Investigator-initiated multinational early-stage innovative clinical trials for paediatric cancer**

- Alignment with BioCanRx's CLIC initiative, **CD22 CAR T cell therapy** clinical trial under cohort B: participants must have a relapsed or refractory B cell acute lymphoblastic leukemia (B-ALL) who are 1-21 years old.
  - The CLIC initiative aims to provide affordable and patient-centric access of CAR T cell therapy to patients across Canada
- We could also **serve as a facilitator of expertise and infrastructure** for the conduct of these clinical trials in Canada and/or with Canadian SMEs.

**Partner Search Form**  
**Horizon Europe**  
**Health**

<b>Keywords specifying your expertise:</b>	<p><b>HORIZON-HLTH-2025-01-IND-01</b>          Biomanufacturing process enhancements          Innovative health adoption pathways          Quality control platform and standardization          Decentralized manufacturing          CAR T cell therapy (GTMP category)          Tumour infiltrating lymphocyte (TIL) therapy (sCTMP category)          Cancer</p> <p><b>HORIZON-HLTH-2025-01-TOOL-02</b>          Cancer vaccines          Exosomes          CMC package          Clinical trial application          Clinical translation          GMP production          Early-phase clinical trials          Translational research</p> <p><b>HORIZON-HLTH-2025-01-TOOL-05</b>          therapeutic vaccines          monoclonal antibodies          RNA based therapies          ATMPs (CAR T cell therapies)          Canadian subject matter expertise and infrastructure</p> <p><b>HORIZON-MISS-2025-02-CANCER-04</b>          Investigator-initiated early-phase clinical trials          CAR T cell therapy          Clinical translation          Innovative health adoption pathway          Accessible treatments</p>
--	--

<b>Commitment offered:</b>	<div> <input checked="" type="checkbox"/> Research           <input type="checkbox"/> Demonstration           <input type="checkbox"/> Training         </div> <div> <input checked="" type="checkbox"/> Technology           <input checked="" type="checkbox"/> Dissemination           <input type="checkbox"/> Other:         </div>
----------------------------	--

<b>Interested in participation in project types:</b>	<div> <input checked="" type="checkbox"/> Research &amp; Innovation Action           <input checked="" type="checkbox"/> Innovation Action           <input type="checkbox"/> SME Instrument         </div>
--	---

**Work Programme research areas: indicate your interest**

<b>Cluster Health</b>
-----------------------

**Partner Search Form**  
**Horizon Europe**  
**Health**

**Do you have other partners for this topic (which partners/country):**

Not yet

**Profile of partner sought**

**Role**

☒ technology development

☒ research

☐ training

☒ dissemination

☐ demonstration

☐ other :

**Country /region**

CANADA

**Expertise required**

We would like to leverage our network expertise to a consortium.

**I agree with the publication of my contact data:**

☒ YES

☐ NO